StocksMedium•28 September 2026•
1 min read
Revvity Stock Closes at $150 Following Human Cell Design Acquisition News
Key Facts
1Revvity shares closed at $150.00 on September 28, 2026, marking a 0.73% decrease.
2The company announced its intention to acquire Human Cell Design, specializing in human cell models for metabolic diseases.
3The acquisition is expected to finalize in Q4 2026, pending regulatory approvals.
Revvity shares closed at $150.00 on September 28, 2026, marking a 0.73% decrease. According to AD HOC NEWS, the company announced its intention to acquire Human Cell Design, a firm specializing in human cell models for metabolic diseases, with the transaction expected to finalize in the fourth quarter of 2026 pending regulatory approvals.
This strategic move follows a period where RVTY shares closed at $151.11 on September 25, 2026, prior to the recent slight decline. AD HOC NEWS reported that the acquisition aims to integrate pancreatic beta cell models into the company's life sciences portfolio, alongside the launch of new detection solutions for type 1 diabetes autoantibodies.